About Centocor

Centocor is harnessing the power of world-leading research and biomanufacturing to deliver innovative biomedicines that transform patients' lives. Centocor has already brought innovation to the treatment of plaque psoriasis, rheumatoid arthritis, psoriatic arthritis, Crohn's disease, pediatric Crohn's disease, ulcerative colitis, and ankylosing spondylitis.

Centocor continues to pioneer new pathways in biomedical research and development. Drug discovery and development efforts focus on Immune Mediated Inflammatory Diseases. Centocor is looking for novel approaches that address the pathology of these diseases.

The world leader in monoclonal antibody production and technology, Centocor has brought critical biologic therapies to patients suffering from debilitating immune disorders. Centocor is a wholly owned subsidiary of Johnson & Johnson, a worldwide manufacturer of healthcare products. 

To learn more about Centocor, please visit our website at www.centocor.com